Automate Your Wheel Strategy on OCUL
With Tiblio's Option Bot, you can configure your own wheel strategy including OCUL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCUL
- Rev/Share 0.3517
- Book/Share 1.5699
- PB 7.249
- Debt/Equity 0.2866
- CurrentRatio 10.2224
- ROIC -0.5513
- MktCap 1812834000.0
- FreeCF/Share -0.8762
- PFCF -12.2136
- PE -10.0033
- Debt/Assets 0.1878
- DivYield 0
- ROE -0.588
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OCUL | William Blair | -- | Outperform | -- | -- | April 8, 2025 |
| Initiation | OCUL | RBC Capital Mkts | -- | Outperform | -- | $17 | March 18, 2025 |
| Initiation | OCUL | Needham | -- | Buy | -- | $15 | March 11, 2025 |
| Initiation | OCUL | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience
Read More
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Read More
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Positive
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Read More
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
Read More
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Read More
About Ocular Therapeutix, Inc. (OCUL)
- IPO Date 2014-07-25
- Website https://www.ocutx.com
- Industry Biotechnology
- CEO Pravin U. Dugel
- Employees 274